Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2023.1055131
Abstract: Introduction Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h),… read more here.
Keywords: hypertension; suspension formulation; tadalafil suspension; suspension ... See more keywords